Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena Marzo-Ortega

Showing results (1-10 of 247) with videos related to

Pageof 25
Sort By:
Lancet (London, England)|April 26, 2025
Research at the centre of UK health-care delivery to fix clinical academiaHelena Marzo-Ortega
Rheumatology (Oxford, England)|October 14, 2020
Axial spondyloarthritis: coming of ageHelena Marzo-Ortega
BMJ (Clinical Research Ed.)|May 20, 2025
Rethinking clinical trial design and electronic health record systems could improve clinical research in the UKHelena Marzo-Ortega
Annals of the Rheumatic Diseases|November 30, 2021
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'Stefan Siebert, Helena Marzo-Ortega
Nature Reviews. Rheumatology|January 26, 2024
Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadowStefan Siebert, Helena Marzo-Ortega
Nature Reviews. Rheumatology|October 26, 2019
Axial spondyloarthritis: time to stop the split 10 years onXabier Michelena, Helena Marzo-Ortega
Skeletal Radiology|June 23, 2012
Ankylosing spondylitis - the changing role of imagingZoe Ash, Helena Marzo-Ortega
Lancet (London, England)|May 10, 2025
Isotretinoin-associated cervical osteophytosis - Authors' replyKamran Naraghi, Helena Marzo-Ortega
Lancet (London, England)|September 21, 2024
Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosaceaKamran Naraghi, Helena Marzo-Ortega
RMD Open|September 19, 2025
Are investigator-initiated clinical trials becoming an 'endangered species'?Helena Marzo-Ortega, Gabriele De Marco
Pageof 25

Showing results (1-10 of 247) with videos related to

Sort By:
Pageof 25
Lancet (London, England)|April 26, 2025
Research at the centre of UK health-care delivery to fix clinical academiaHelena Marzo-Ortega
Rheumatology (Oxford, England)|October 14, 2020
Axial spondyloarthritis: coming of ageHelena Marzo-Ortega
BMJ (Clinical Research Ed.)|May 20, 2025
Rethinking clinical trial design and electronic health record systems could improve clinical research in the UKHelena Marzo-Ortega
Annals of the Rheumatic Diseases|November 30, 2021
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'Stefan Siebert, Helena Marzo-Ortega
Nature Reviews. Rheumatology|January 26, 2024
Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadowStefan Siebert, Helena Marzo-Ortega
Nature Reviews. Rheumatology|October 26, 2019
Axial spondyloarthritis: time to stop the split 10 years onXabier Michelena, Helena Marzo-Ortega
Skeletal Radiology|June 23, 2012
Ankylosing spondylitis - the changing role of imagingZoe Ash, Helena Marzo-Ortega
Lancet (London, England)|May 10, 2025
Isotretinoin-associated cervical osteophytosis - Authors' replyKamran Naraghi, Helena Marzo-Ortega
Lancet (London, England)|September 21, 2024
Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosaceaKamran Naraghi, Helena Marzo-Ortega
RMD Open|September 19, 2025
Are investigator-initiated clinical trials becoming an 'endangered species'?Helena Marzo-Ortega, Gabriele De Marco
Pageof 25